A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, bladder transitional cell carcinoma, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder	Not yet recruiting	Phase 1	2026-07-24		NCT07725796

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.	1

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Brigham and Women's Hospital	Boston	United States	511
East Valley Urology Center of Arizona	Queen Creek	United States	4
Ichan School of Medicine at Mount Sinai	New York	United States	14
Michael G Oefelein Clinical Trials	Bakersfield	United States	3
START Carolinas	Myrtle Beach	United States	3
SUNY Upstate Medical University	Syracuse	United States	68
University of Nebraska Medical Center	Omaha	United States	397
University of Pennsylvania-Perelman Center for Advanced Medicine	Philadelphia	United States	1
UPNT Research Institute	Arlington	United States	4
Urology Austin	Austin	United States	8
Urology Center of Southern California	Murrieta	United States	3